Tuition from
₹43.7 L
per year, 4 courses
Courses
4
Founded
1872
Faculty at Illinois College of Optometry
For over three decades, Michael Chaglasian, OD, FAAO has been a cornerstone of the ICO community. Now serving as Chief of Innovative Technology and Data Science, he’s leading the institution into a new era of digital discovery. From pioneering research in glaucoma to exploring the power of artificial intelligence in clinical care, Dr. Chaglasian bridges traditional optometric practice with the technologies shaping its future. A founding figure in advancing glaucoma education nationwide, his leadership continues to inspire both faculty and students.
In this Faculty Spotlight, we take a closer look at Dr. Chaglasian’s journey: from his early days as a SUNY–trained clinician, to his current work with AI–powered diagnostic tools that could transform the future of optometry.
You’ve recently taken on the role of Chief of Innovative Technology and Data Science at ICO. How does this position build upon your past work in glaucoma research?
My new role reflects both the continuity and the evolution of my career at ICO. I’ve been here for about 30 years, primarily focused on glaucoma care, research, and education. Now, as Chief of Innovative Technology and Data Science, I’m exploring how artificial intelligence and digital tools can elevate clinical decision–making and patient outcomes, particularly within glaucoma management.
AI in health care can feel intimidating to some, but I see it as an opportunity. The goal isn’t to replace clinicians, it’s to empower them. At ICO, we’re in the early stages of building and validating AI algorithms that can assist doctors in interpreting patient data more effectively. For example, glaucoma diagnosis relies on the synthesis of multiple datasets, from visual fields to OCT scans to intraocular pressure readings, and AI has the potential to analyze those variables collectively, identifying subtle trends that even trained eyes might miss.
Of course, glaucoma remains my primary focus. It’s a disease that demands early detection, and optometry is uniquely positioned to make that possible. By integrating AI into routine eye care, we can move from reactive to proactive management by detecting subtle nerve fiber changes or pressure trends before vision loss occurs. That’s the promise that drives me today: equipping the next generation of optometrists with tools that not only enhance their clinical confidence but also expand what’s possible for patient care.
Beyond your research, you’ve been instrumental in advancing glaucoma education both on and off campus. What continues to motivate your involvement in that mission?
Glaucoma is often called the “silent thief of sight,” and that phrase captures the urgency of why education is so critical. When I started at ICO, I quickly realized that there wasn’t a dedicated forum within optometry focused exclusively on this disease. Along with several colleagues, I helped establish the Optometric Glaucoma Society (OGS) more than 20 years ago. Today, as its Executive Director, I’m proud to see it flourish into an organization that brings together over 150 clinicians, educators, and researchers.
In this Faculty Spotlight, we take a closer look at Dr. Chaglasian’s journey: from his early days as a SUNY–trained clinician, to his current work with AI–powered diagnostic tools that could transform the future of optometry.
You’ve recently taken on the role of Chief of Innovative Technology and Data Science at ICO. How does this position build upon your past work in glaucoma research?
My new role reflects both the continuity and the evolution of my career at ICO. I’ve been here for about 30 years, primarily focused on glaucoma care, research, and education. Now, as Chief of Innovative Technology and Data Science, I’m exploring how artificial intelligence and digital tools can elevate clinical decision–making and patient outcomes, particularly within glaucoma management.
AI in health care can feel intimidating to some, but I see it as an opportunity. The goal isn’t to replace clinicians, it’s to empower them. At ICO, we’re in the early stages of building and validating AI algorithms that can assist doctors in interpreting patient data more effectively. For example, glaucoma diagnosis relies on the synthesis of multiple datasets, from visual fields to OCT scans to intraocular pressure readings, and AI has the potential to analyze those variables collectively, identifying subtle trends that even trained eyes might miss.
Of course, glaucoma remains my primary focus. It’s a disease that demands early detection, and optometry is uniquely positioned to make that possible. By integrating AI into routine eye care, we can move from reactive to proactive management by detecting subtle nerve fiber changes or pressure trends before vision loss occurs. That’s the promise that drives me today: equipping the next generation of optometrists with tools that not only enhance their clinical confidence but also expand what’s possible for patient care.
Beyond your research, you’ve been instrumental in advancing glaucoma education both on and off campus. What continues to motivate your involvement in that mission?
Glaucoma is often called the “silent thief of sight,” and that phrase captures the urgency of why education is so critical. When I started at ICO, I quickly realized that there wasn’t a dedicated forum within optometry focused exclusively on this disease. Along with several colleagues, I helped establish the Optometric Glaucoma Society (OGS) more than 20 years ago. Today, as its Executive Director, I’m proud to see it flourish into an organization that brings together over 150 clinicians, educators, and researchers.
Imported from public sources and may be a cycle out of date. Confirm on the official site.
Similar universities in United States
Nearest by ranking, so these are the ones you would realistically compare against.
